Subscribe To
CUBT / CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE
CUBT News
By GlobeNewsWire
October 7, 2021
CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies more_horizontal
By GlobeNewsWire
October 7, 2021
CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies more_horizontal
By GlobeNewsWire
October 7, 2021
CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies more_horizontal
By PRNewsWire
October 7, 2021
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine
BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the more_horizontal
By PRNewsWire
October 7, 2021
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine
BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the more_horizontal
By PRNewsWire
October 7, 2021
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine
BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the more_horizontal